AstraZeneca
Anifrolumab
Lupus Nephritis
Countdown
234days
Phase 3 readout · Feb 26, 2027
What's at stake
Phase 3 trial results for Anifrolumab in Lupus Nephritis are due Feb 26, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05138133: Phase 3 trial, sponsor AstraZeneca, drug Anifrolumab. Primary completion date 2027-02-26 (estimated).”